• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production.

作者信息

Yanai Hidekatsu, Katsuyayama Hisayuki

机构信息

Department of Internal Medicine, National Center for Global Health and Medicine Kohnodai Hospital, Chiba, Japan.

出版信息

J Clin Med Res. 2017 Feb;9(2):178-179. doi: 10.14740/jocmr2857w. Epub 2016 Dec 31.

DOI:10.14740/jocmr2857w
PMID:28090235
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5215023/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9012/5215023/405a48cfb12c/jocmr-09-178-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9012/5215023/405a48cfb12c/jocmr-09-178-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9012/5215023/405a48cfb12c/jocmr-09-178-g001.jpg

相似文献

1
A Possible Mechanism for Renoprotective Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Elevation of Erythropoietin Production.钠-葡萄糖协同转运蛋白2抑制剂肾脏保护作用的一种可能机制：促红细胞生成素生成增加。
J Clin Med Res. 2017 Feb;9(2):178-179. doi: 10.14740/jocmr2857w. Epub 2016 Dec 31.
2
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys.钠-葡萄糖协同转运蛋白2抑制剂治疗期间血细胞比容升高表明糖尿病肾病肾小管间质功能恢复
J Clin Med Res. 2016 Dec;8(12):844-847. doi: 10.14740/jocmr2760w. Epub 2016 Oct 26.
3
Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.自发性糖尿病 Torii 肥胖大鼠中钠-葡萄糖共转运蛋白 2 抑制对肾小球滤过率的急性和直接影响。
Biol Pharm Bull. 2019;42(10):1707-1712. doi: 10.1248/bpb.b19-00351.
4
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.托格列净是一种钠-葡萄糖协同转运蛋白2的选择性抑制剂，可抑制KKAy/Ta小鼠（肥胖型2型糖尿病动物）的肾脏损伤。
Diab Vasc Dis Res. 2016 Nov;13(6):438-441. doi: 10.1177/1479164116657304. Epub 2016 Jul 12.
5
Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials.钠-葡萄糖协同转运蛋白 2 抑制与肾缺血：对未来临床试验的影响。
Kidney Int. 2018 Sep;94(3):459-462. doi: 10.1016/j.kint.2018.05.026.
6
Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.钠-葡萄糖协同转运蛋白2抑制剂导致血细胞比容升高的可能机制及相关的肾脏和心血管有益效应
Circulation. 2019 Apr 23;139(17):1985-1987. doi: 10.1161/CIRCULATIONAHA.118.038881.
7
Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.2 型糖尿病患者钠-葡萄糖共转运蛋白 2 抑制后肾脏对酮体的处理。
Diabetes Care. 2017 Jun;40(6):771-776. doi: 10.2337/dc16-2724. Epub 2017 Mar 21.
8
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.钠-葡萄糖协同转运蛋白2抑制剂预期的肾脏保护作用
Intern Med. 2018 Aug 1;57(15):2105-2114. doi: 10.2169/internalmedicine.9842-17. Epub 2018 Feb 28.
9
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits.钠-葡萄糖协同转运蛋白 2 抑制剂相关心血管获益的潜在机制。
Am J Cardiol. 2019 Dec 15;124 Suppl 1:S36-S44. doi: 10.1016/j.amjcard.2019.10.028.
10
Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice.钠-葡萄糖协同转运蛋白2抑制剂托格列净对肥胖和糖尿病小鼠二乙基亚硝胺诱导的肝脏肿瘤发生的预防作用
Oncotarget. 2017 Apr 6;8(35):58353-58363. doi: 10.18632/oncotarget.16874. eCollection 2017 Aug 29.

引用本文的文献

1
Significance of Endothelial Dysfunction Amelioration for Sodium-Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients.内皮功能障碍改善对钠-葡萄糖协同转运蛋白2抑制剂诱导糖尿病患者心力衰竭和慢性肾脏病病情改善的意义
Metabolites. 2023 Jun 8;13(6):736. doi: 10.3390/metabo13060736.
2
Renoprotective effect of chronic treatment with sodium-glucose cotransporter 2 inhibitors and its associated factors in Japanese patients with chronic heart failure and diabetes.钠-葡萄糖协同转运蛋白2抑制剂长期治疗对日本慢性心力衰竭合并糖尿病患者的肾脏保护作用及其相关因素
Int J Cardiol Heart Vasc. 2022 Nov 26;43:101152. doi: 10.1016/j.ijcha.2022.101152. eCollection 2022 Dec.
3

本文引用的文献

1
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys.钠-葡萄糖协同转运蛋白2抑制剂治疗期间血细胞比容升高表明糖尿病肾病肾小管间质功能恢复
J Clin Med Res. 2016 Dec;8(12):844-847. doi: 10.14740/jocmr2760w. Epub 2016 Oct 26.
2
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
3
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
SGLT2 抑制剂的心脏-肾脏保护机制概述。
Int J Mol Sci. 2022 Mar 26;23(7):3651. doi: 10.3390/ijms23073651.
4
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy.2型糖尿病患者中，钠-葡萄糖协同转运蛋白2（SGLT2）抑制带来的心血管益处不会因与药物治疗相关的磷酸盐通量而受损。
World J Cardiol. 2021 Dec 26;13(12):676-694. doi: 10.4330/wjc.v13.i12.676.
5
Acute Effects of Preventing Heart Failure by Sodium-Glucose Cotransporter 2 Inhibitors.钠-葡萄糖协同转运蛋白2抑制剂预防心力衰竭的急性效应
Cardiol Res. 2021 Oct;12(5):324-326. doi: 10.14740/cr1315. Epub 2021 Aug 31.
6
SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?钠-葡萄糖协同转运蛋白 2 抑制剂及其在心力衰竭中的作用机制——谜团是否已被揭开？
Curr Heart Fail Rep. 2021 Oct;18(5):315-328. doi: 10.1007/s11897-021-00529-8. Epub 2021 Sep 15.
7
Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂的多器官保护作用。
Int J Mol Sci. 2021 Apr 23;22(9):4416. doi: 10.3390/ijms22094416.
8
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.达格列净对伴或不伴糖尿病的心力衰竭患者心力衰竭恶化和心血管死亡的影响。
JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906.
9
Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease.促红细胞生成素抑制 SGK1 依赖性 TH17 诱导和 TH17 依赖性肾脏疾病。
JCI Insight. 2019 Apr 23;5(10):127428. doi: 10.1172/jci.insight.127428.
10
SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与心血管保护：解读当前结局试验中的经验与差距以及SGLT-2抑制剂与胰高血糖素样肽-1（GLP-1）受体激动剂联合使用的潜在益处
J Clin Med Res. 2018 Aug;10(8):615-625. doi: 10.14740/jocmr3467w. Epub 2018 Jun 27.
钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者代谢参数的影响：一项基于图表的分析。
J Clin Med Res. 2016 Mar;8(3):237-43. doi: 10.14740/jocmr2467w. Epub 2016 Jan 26.
4
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
5
Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.促红细胞生成素可改善 db/db 糖尿病小鼠晚期糖尿病肾病足细胞损伤。
Am J Physiol Renal Physiol. 2013 Sep 15;305(6):F911-8. doi: 10.1152/ajprenal.00643.2012. Epub 2013 Jul 3.
6
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.达格列净：一种具有利尿作用的葡萄糖调节药物，适用于 2 型糖尿病患者。
Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.
7
A crosstalk between macroangiopathy and microangiopathy in type 2 diabetes.
Int J Cardiol. 2013 Sep 20;168(1):550-1. doi: 10.1016/j.ijcard.2013.01.199. Epub 2013 Mar 1.
8
Erythropoietin protects podocytes from damage by advanced glycation end-products.促红细胞生成素通过抑制晚期糖基化终产物保护足细胞免受损伤。
Nephron Exp Nephrol. 2011;117(1):e21-30. doi: 10.1159/000319653. Epub 2010 Aug 4.
9
Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat.重组人促红细胞生成素的长期治疗对链脲佐菌素诱导的糖尿病大鼠具有除造血作用之外的肾脏保护作用。
Eur J Pharmacol. 2009 Jun 10;612(1-3):106-14. doi: 10.1016/j.ejphar.2009.03.065. Epub 2009 Apr 5.